[Redefining the 'E' in EBM.]

In the last decade, evidence has accumulated that journal publications of commercial clinical trials cannot be trusted. We are not able to publish a 10-pager based on a regulatory report without a radical selection of information and data. This introduces unfathomable bias, sometimes so bad that it distorts single trial reports, and the findings of systematic reviews. To solve the problem we should make an index of all prospective comparative studies we could find to obtain a near-complete overview: it is complex, but rewarded with completeness and reliability.